NCT03351699View on ClinicalTrials.gov

Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 18, 2018

Primary Completion Date

November 2, 2018

Study Completion Date

November 2, 2018

Conditions
HIV-1 Infection
Interventions
DRUG

MK-4250

MK-4250 tablets for oral administration

Trial Locations (1)

10117

Charite Research Organisation GmbH ( Site 0001), Berlin

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03351699 - Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002) | Biotech Hunter | Biotech Hunter